Northwest Biotherapeutics Stock Buy Hold or Sell Recommendation
| NWBO Stock | USD 0.27 0.01 3.57% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Northwest Biotherapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Northwest Biotherapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Northwest Biotherapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Northwest and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Northwest Biotherapeutics. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Northwest |
Execute Northwest Biotherapeutics Buy or Sell Advice
The Northwest recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Northwest Biotherapeutics. Macroaxis does not own or have any residual interests in Northwest Biotherapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Northwest Biotherapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Northwest Biotherapeutics Trading Alerts and Improvement Suggestions
| Northwest Biotherapeutics generated a negative expected return over the last 90 days | |
| Northwest Biotherapeutics has some characteristics of a very speculative penny stock | |
| Northwest Biotherapeutics has high historical volatility and very poor performance | |
| Northwest Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Northwest Biotherapeutics currently holds 25.16 M in liabilities. Northwest Biotherapeutics has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Northwest Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Northwest Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Northwest Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Northwest to invest in growth at high rates of return. When we think about Northwest Biotherapeutics' use of debt, we should always consider it together with cash and equity. | |
| Northwest Biotherapeutics currently holds about 9.43 M in cash with (38.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Northwest Biotherapeutics Returns Distribution Density
The distribution of Northwest Biotherapeutics' historical returns is an attempt to chart the uncertainty of Northwest Biotherapeutics' future price movements. The chart of the probability distribution of Northwest Biotherapeutics daily returns describes the distribution of returns around its average expected value. We use Northwest Biotherapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Northwest Biotherapeutics returns is essential to provide solid investment advice for Northwest Biotherapeutics.
| Mean Return | -0.45 | Value At Risk | -3.85 | Potential Upside | 4.00 | Standard Deviation | 3.65 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Northwest Biotherapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Northwest Biotherapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Northwest Biotherapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Northwest Biotherapeutics' price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Northwest otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.56 | |
β | Beta against Dow Jones | 0.85 | |
σ | Overall volatility | 3.47 | |
Ir | Information ratio | -0.16 |
Northwest Biotherapeutics Volatility Alert
Northwest Biotherapeutics exhibits very low volatility with skewness of 1.09 and kurtosis of 4.88. Northwest Biotherapeutics is a potential penny stock. Although Northwest Biotherapeutics may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Northwest Biotherapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Northwest instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Northwest Biotherapeutics Fundamentals Vs Peers
Comparing Northwest Biotherapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Northwest Biotherapeutics' direct or indirect competition across all of the common fundamentals between Northwest Biotherapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Northwest Biotherapeutics or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Northwest Biotherapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Northwest Biotherapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Northwest Biotherapeutics to competition |
| Fundamentals | Northwest Biotherapeutics | Peer Average |
| Return On Asset | -1.26 | -0.14 |
| Profit Margin | 52.10 % | (1.27) % |
| Operating Margin | (54.95) % | (5.51) % |
| Current Valuation | 1.03 B | 16.62 B |
| Shares Outstanding | 1.05 B | 571.82 M |
| Shares Owned By Insiders | 10.04 % | 10.09 % |
| Shares Owned By Institutions | 0.23 % | 39.21 % |
| Number Of Shares Shorted | 14.14 M | 4.71 M |
| Price To Earning | 58.17 X | 28.72 X |
| Price To Sales | 858.96 X | 11.42 X |
| Revenue | 1 M | 9.43 B |
| Gross Profit | 1 M | 27.38 B |
| EBITDA | 184.72 M | 3.9 B |
| Net Income | 179.13 M | 570.98 M |
| Cash And Equivalents | 9.43 M | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 25.16 M | 5.32 B |
| Debt To Equity | (16.14) % | 48.70 % |
| Current Ratio | 0.10 X | 2.16 X |
| Book Value Per Share | (0.10) X | 1.93 K |
| Cash Flow From Operations | (38.3 M) | 971.22 M |
| Short Ratio | 13.54 X | 4.00 X |
| Earnings Per Share | (0.06) X | 3.12 X |
| Target Price | 5.0 | |
| Number Of Employees | 19 | 18.84 K |
| Beta | -0.0115 | -0.15 |
| Market Capitalization | 705.3 M | 19.03 B |
| Total Asset | 40.16 M | 29.47 B |
| Retained Earnings | (862.01 M) | 9.33 B |
| Working Capital | (40.83 M) | 1.48 B |
| Current Asset | 24.1 M | 9.34 B |
| Current Liabilities | 64.93 M | 7.9 B |
| Z Score | -0.6 | 8.72 |
Northwest Biotherapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Northwest . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Northwest Biotherapeutics Buy or Sell Advice
When is the right time to buy or sell Northwest Biotherapeutics? Buying financial instruments such as Northwest OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Northwest Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hybrid Mix Funds Thematic Idea Now
Hybrid Mix Funds
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.